Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma

NCT05109052 is registered in ClinicalTrials.gov with University of Rochester as lead sponsor.

NCT NCT05109052
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05109052 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma
Lead sponsor
University of Rochester
Phase
Phase 1/2
Overall status
Withdrawn
Start date
September 20, 2022
Completion date
December 31, 2028
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of liver, hepatocellular carcinoma